Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat

Cancer Prevention Research

Volumn 8, Issue 6, 2015, Pages 518-527

  Zhu, Zongjian ^a   Jiang, Weiqin ^a   Thompson, Matthew D ^b   Echeverria, Dimas ^a   McGinley, John N ^a   Thompson, Henry J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFORMIN; GLUCOSE; INSULIN; METFORMIN; METHYLNITROSOUREA; PHENFORMIN; ANTIDIABETIC AGENT; CARCINOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INCIDENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG LIVER LEVEL; DRUG MUSCLE LEVEL; DRUG TUMOR LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMICALLY INDUCED; DRUG EFFECTS; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BUFORMIN; CARCINOGENS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HYPOGLYCEMIC AGENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; METFORMIN; PHENFORMIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84941795503     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0121     Document Type: Article

References (37)

1. Azvolinsky A. Repurposing to fight cancer: the metformin-prostate cancer connection. J Natl Cancer Inst 2014;106:dju030.
2. Yue W, Yang CS, Dipaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res 2014;7:388-97.
3. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24:469-80.
4. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8:909-15.
5. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009;8:2031-40.
6. Thompson MD, Thompson HJ. A systems pharmacokinetic and pharmacodynamic approach to identify opportunities and pitfalls in energy stress-mediated chemoprevention: the use of metformin and other biguanides. Curr Drug Targets 2012;13:1876-84.
7. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010;9:188-97.
8. Zhu Z, Jiang W, Thompson MD, McGinley JN, Thompson HJ. Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog 2011;10:17.
9. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 2010;3:1060-5.
10. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2:778-90.
11. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256-60.
12. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69.
13. Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011;286:1-11.
14. Vytla VS, Ochs RS. Metformin increases mitochondrial energy formation in L6 muscle cell cultures. J Biol Chem 2013;288:20369-77.
15. Lanaspa MA, Cicerchi C, Garcia G, Li N, Roncal-Jimenez CA, Rivard CJ, et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS One 2012;7:e48801.
16. Anisimov VN. Effect of buformin on the life span, estrous cycle, and spontaneous tumors. Vop Onkol 1980;26:42-8.
17. Anisimov VN, Dilman VM. Inhibitory effect of phenformin in the development of mammarytumors induced by N-nitrosomethylurea. Vop Onkol 1980;26:58.
18. Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr 1997;127:838S-41S.
19. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-51.
20. Reeves PG, Rossow KL, Lindlauf J. Development and testing of the AIN-93 purified diets for rodents: results on growth, kidney calcification and bone mineralization in rats and mice. J Nutr 1993;123:1923-31.
21. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 2009;69:8175-82.
22. Beckmann R, Lintz W, Schmidt-Bothelt E. Evaluationof asustained release form of the oral antidiabetic butylbiguanide (Silubin-retard). Eur J Clin Pharmacol 1971;3:221-8.
23. Hunt JA, Catellier C, Dupre J, Gardiner RJ, McKendry JB, Toews CJ, et al. The use of phenformin and metformin. Can Med Assoc J 1977;117:429-30.
24. McKendry JB, KUWAYTI K, RADO PP. Clinical experience with DBI (phenformin) in the management of diabetes. Can Med Assoc J 1959;80:773-8.
25. Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 1995;16:2407-11.
26. Singh M, McGinley JN, Thompson HJ. A comparison of the histopathology of premalignant and malignant mammary gland lesions induced in sexually immature rats with those occurring in the human. Lab Invest 2000;80:221-31.
27. Thompson HJ, Singh M, McGinley J. Classification of premalignant and malignant lesions developing in the rat mammary gland after injection of sexually immature rats with 1-methyl-1-nitrosourea. J Mammary Gland Biol Neoplasia 2000;5:201-10.
28. Sokal RR, Rohlf FJ. Biometry the principles and practice of statistics in biological research. 3rd ed. New York: W. H. Freeman; 1995.
29. Conover WJ, Iman RL. Rank Transformations as a Bridge between Parametric and Nonparametric Statistics. The American Statistician 1981;35:124-9.
30. Trygg J, Wold S. Orthogonal projections to latent structures (OPLS). Journal of Chemometrics 2002;16:119-28.
31. Wiklund S. Multivariate data analysis and modeling in "omics." Umea, Sweden: Umetrics; 2008.
32. Wiklund S, Johansson E, Sjostrom L, Mellerowicz EJ, Edlund U, Shockcor JP, et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008;80:115-22.
33. User's guide to Simca-P, Simca-Pp. 11th ed. Umea, Sweden: Umetrics AB; 2005.
34. Morrison DF. Multivariate statistical methods. 3rd ed. New York: McGraw-Hill Publishing Co.; 1990.
35. Gabrielsson J, Jonsson H, Airiau C, Schmidt B, Escott R, Trygg J. OPLS methodology for analysis of pre-processing effects on spectroscopic data. Chemometrics and Intelligent Laboratory Systems 2006;84:153-8.
36. Tushar, Roy SS, Pratihar DK. Determination of optimal clusters using a genetic algorithm. In: Taniar D, editor. Data mining and knowledge discovery technologies. Hershey, PA: IGI Publishing; 2008. p. 98-117.
37. Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, et al. Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. Cancer Prev Res 2015;8:231-9.